Promising Results for CAH Patients Treated with Crinecerfont Revealed in Study

A recent study published in the New England Journal of Medicine has revealed promising results for patients with congenital adrenal hyperplasia (CAH) who were treated with crinecerfont. The research showed that crinecerfont led to a significant decrease in daily glucocorticoid dose compared to a placebo. The study, presented at the annual meeting of the Endocrine Society, demonstrated a 27.3% reduction in glucocorticoid dose with crinecerfont therapy, highlighting its potential benefits for adults with classic CAH.